Page 15 - Clinical Obstetrics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Clinical obstetrics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Clinical Obstetrics Today - Breaking & Trending Today

Mostly positive phase III data prompts Vertex to seek an NDA

Despite Vertex Pharmaceuticals Inc.’s mostly positive phase III study results of a non-opioid for treating moderate to severe acute pain, the data for a key secondary endpoint show VX-548 is not as effective as Vicodin (hydrocodone, Abbvie Inc.). Neither of two randomized, double-blind, placebo-controlled, pivotal studies, one treating patients after abdominoplasty surgery and one after bunionectomy surgery, met the key secondary endpoint of VX-548 being superior to hydrocodone bitartrate/acetaminophen in patients’ pain levels. ....

Abbvie Inc , Vertex Pharmaceuticals Inc , Vertex Pharmaceuticals , Vertex Pharmaceuticals Inc , Vx 548 , Neurology Psychiatric , Abbvie Inc , Non Opioids , Pain Management ,

Corbus rockets on early clinical data for next-gen Nectin-4 ADC candidate

Shares of Corbus Pharmaceuticals Inc. (NASDAQ:CRBP) doubled on opening Jan. 26 and ended the day up a whopping 249% as investors got a look at data from a first-in-human study testing next-generation Nectin-4-targeted antibody-drug conjugate (ADC) CRB-701. Licensed from CSPC Pharmaceutical Group for $7.5 million up front in February 2023, CRB-701 has IND clearance from the U.S. FDA, and Corbus plans to start its own clinical testing in the first quarter of 2024. ....

Corbus Pharmaceuticals Inc , Corbus Pharmaceuticals , Corbus Pharmaceuticals Holdings Inc , Cervical Cancer , Nectin 4 , Cspc Pharmaceutical Group Ltd , Crb 701 , Urothelial Cancer , Asco Gi 2024 , Antibody Drug Conjugate ,

Hear here: Lilly's Akouos gene therapy restores hearing loss in an 11-year-old

The hearing has returned for the first person who has received gene therapy for treating genetic hearing loss in the U.S. Initial results from Akouos Inc.’s phase I/II study showed that within 30 days of receiving AK-OTOF-101, pharmacologic hearing was restored to an 11-year-old who had profound hearing loss from birth. ....

Akouos Inc , Akouos Inc , Ak Otof 101 , Eli Lilly And Co , Hearing Loss , Congenital Hearing Loss , Decibel Therapeutics Inc , Regeneron Pharmaceuticals Inc , Gene Therapy ,

UST, TW hospital collaborate on pioneering telomere clinical study

THE University of Santo Tomas (UST) and Hualien Tzu Chi Hospital and Medical Center in Taiwan have joined forces to conduct a clinical study on telomeres. ....

Hualien Tzu Chi , University Of Santo Tomas , Santo Tomas , Hualien Tzu Chi Hospital , Medical Center ,

Dxcover launches troika of trials to evaluate efficacy of cancer test

Dxcover Ltd. initiated three pivotal trials to measure the efficacy of its liquid biopsy platform for early detection of brain, colorectal and lung cancers. The company hopes the trials will provide the evidence needed to gain regulatory approval and begin commercial operations of its diagnostic technology in Europe and the U.S. ....

Dxcover Ltd , Bioworld Medtech , Brain Cancer , Colorectal Cancer , Dxcover Ltd , Lung Cancer ,